Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature.
Indications for the use of radiotherapy in the management of a variety of benign intracranial neoplastic and nonneoplastic pathologies are increasing. Although the short-term risks are minimal, the long-term risks of radiation-induced de novo secondary neoplasms or malignant progression of the primary benign tumor need to be considered. There are currently 19 reported cases of tumors linked with stereotactic radiotherapy/radiosurgery, to which we add our second institutional experience of a patient who succumbed to a glioblastoma multiforme (GBM) after stereotactic radiotherapy for an acoustic neuroma (AN). Review of these 20 cases revealed 10 de novo secondary tumors, of which eight were malignant, with six being malignant gliomas. The majority of the cases (14 of 20) involved AN, with most being in patients with neurofibromatosis-2 (NF2; 8 of 14), reflecting the large numbers and long-term use of radiotherapy for AN. Accelerated growth of the primary benign AN, some 2 to 6 years after focused radiotherapy, was found in six of eight NF2 patients, with pathological verification of a malignant nerve sheath tumor documented in most. The exact carcinogenic risk after radiotherapy is unknown but likely extremely low. However, the risk is not zero and requires discussion with the patient, with specific consideration in young patients and those with a cancer predisposition.
Balasubramaniam
Anandh
A
Arthur and Sonia Labatt Brain Tumor Center, Hospital for Sick Children, University of Toronto, 399 Bathurst St., 4W-446, Toronto, ON M5T-2S8, Canada.
Shannon
Patrick
P
Hodaie
Mojgan
M
Laperriere
Normand
N
Michaels
Howard
H
Guha
Abhijit
A
D001932:Brain Neoplasms / Q000209:etiology* / Q000473:pathology; D005260:Female; D005909:Glioblastoma / Q000209:etiology* / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009381:Neoplasms, Radiation-Induced / Q000209:etiology* / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000209:etiology* / Q000473:pathology; D009464:Neuroma, Acoustic / Q000601:surgery*; D016634:Radiosurgery / Q000009:adverse effects*
Stereotact Funct Neurosurg. 1999;72 Suppl 1:2-10
10681685
Otol Neurotol. 2006 Feb;27(2):213-9
16436992
Am J Otol. 2000 May;21(3):364-70
10821550
Br J Neurosurg. 2000 Apr;14(2):93-5
10889878
Lancet. 2000 Nov 4;356(9241):1576-7
11075777
J Neurosurg. 2001 May;94(5):816-21
11354416
J Neurosurg. 2001 Sep;95(3):518-21
11565878
J Neurosurg. 2001 Oct;95(4):710-3
11596968
Neoplasia. 2002 Jul-Aug;4(4):279-90
12082543
Lancet. 2002 Jul 27;360(9329):309-10
12147377
Laryngoscope. 2002 Jun;112(6):948-50
12160289
Br J Neurosurg. 2002 Jun;16(3):284-9
12201399
Neurosurgery. 2003 Feb;52(2):296-307; discussion 307-8
12535357
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62
12679524
Neurosurgery. 2003 Jun;52(6):1291-6; discussion 1296-7
12762874
Neurosurgery. 2003 Jun;52(6):1436-40; discussion 1440-2
12762888
Surg Neurol. 2003 Jul;60(1):60-7; discussion 67
12865017
Minim Invasive Neurosurg. 2003 Aug;46(4):254-6
14506573
J Clin Pathol. 2004 Jan;57(1):109-10
14693854
Neurol Med Chir (Tokyo). 2004 Jan;44(1):29-32
14959934
J Neurooncol. 2004 Feb;66(3):301-5
15015661
Neurochirurgie. 2004 Jun;50(2-3 Pt 2):414-20
15179297
Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):928-42
15234026
Oncogene. 2004 Aug 26;23(39):6541-7
15221010
Cancer. 1984 Feb 1;53(3):426-9
6581853
Neurosurgery. 1985 Sep;17(3):436-45
2995867
Cancer. 1987 Apr 1;59(7):1274-82
3815303
N Engl J Med. 1990 Jul 12;323(2):127-9
2359422
BMJ. 1992 May 23;304(6838):1343-6
1611331
Tumori. 1992 Apr 30;78(2):143-6
1523707
Cancer. 1993 Oct 1;72(7):2227-33
8374881
Cancer. 1998 Jan 1;82(1):8-34
9428476
J Neurosurg. 1998 Oct;89(4):653-8
9761063
Cancer Res. 1999 Mar 1;59(5):1008-14
10070956
J Neurooncol. 2004 Aug-Sep;69(1-3):335-49
15527099
Radiat Res. 2005 Apr;163(4):424-32
15799699
Cancer Cell. 2005 Oct;8(4):271-3
16226702
Br J Cancer. 2000 Feb;82(4):998
10732777